Cadrenal Therape Stock Price, News & Analysis

Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a biopharmaceutical company developing anticoagulant therapies for rare and high-risk patient populations, and its news flow reflects this specialized focus. The CVKD news page on Stock Titan aggregates company announcements, sponsored coverage, and regulatory updates related to its clinical-stage pipeline.

Readers can expect news centered on Cadrenal’s three main assets: VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia (HIT); tecarfarin, an oral vitamin K antagonist for chronic use in patients with kidney dysfunction or left ventricular assist devices; and frunexian, a parenteral Factor XIa antagonist positioned for acute hospital settings. Company communications often highlight regulatory designations such as Orphan Drug and Fast Track status, clinical trial progress, and portfolio-expanding transactions.

News items also cover corporate developments, including participation in healthcare investor conferences, partnering outreach, and board-level appointments. Financial updates, such as quarterly results and capital-raising activities disclosed via press releases and Form 8-K filings, provide additional context on how Cadrenal is funding and prioritizing its development programs.

For investors, clinicians, and researchers following the evolution of anticoagulation therapies, the CVKD news feed offers a consolidated view of Cadrenal’s milestones across chronic, acute, and immune-mediated indications. Bookmark this page to review new press releases, sponsored analytical pieces, and SEC-related announcements as they are released, and to track how the company’s strategy and pipeline advance over time.